Anticancer Activity of Nano-formulated Orlistat-Dopamine Conjugates Through Self-Assembly

Shuang Chen, Jun F. Liang

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Orlistat, an FDA-approved fatty acid inhibitor for obesity treatment, demonstrates certain low and greatly varied anticancer abilities. In a previous study, we revealed a synergistic effect between orlistat and dopamine in cancer treatment. Here, orlistat-dopamine conjugates (ODCs) with defined chemical structures were synthesized. The ODC by design underwent polymerization and self-assembly in the presence of oxygen to form nano-sized particles (Nano-ODCs) spontaneously. The resulted Nano-ODCs of partial crystalline structures demonstrated good water dispersion to form stable Nano-ODC suspensions. Because of the bioadhesive property of the catechol moieties, once administered, Nano-ODCs were quickly accumulated on cell surfaces and efficiently uptaken by cancer cells. In the cytoplasm, Nano-ODC experienced biphasic dissolution followed by spontaneous hydrolysis to release intact orlistat and dopamine. Besides elevated levels of intracellular reactive oxygen species (ROS), the co-localized dopamine also induced mitochondrial dysfunctions through monoamine oxidases (MAOs)-catalyzed dopamine oxidation. The strong synergistic effects between orlistat and dopamine determined a good cytotoxicity activity and a unique cell lysis mechanism, explaining the distinguished activity of Nano-ODC to drug-sensitive and -resistant cancer cells. This new technology-enabled orlistat repurposing will contribute to overcoming drug resistance and the improvement of cancer chemotherapy.

Original languageEnglish
Pages (from-to)581-593
Number of pages13
JournalBioconjugate Chemistry
Volume34
Issue number3
DOIs
StatePublished - 15 Mar 2023

Fingerprint

Dive into the research topics of 'Anticancer Activity of Nano-formulated Orlistat-Dopamine Conjugates Through Self-Assembly'. Together they form a unique fingerprint.

Cite this